Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 19INDUSTRY 6OTHER_GOV 2NIH 1NETWORK 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rare Diseases 1Gastrointestinal Diseases 1Crohn Disease 1

Interventions

Exercise 6pembrolizumab 5enzalutamide 4Docetaxel 4Colonoscopy 4Celecoxib 4sargramostim 3apalutamide 3Prednisone 3Methods 3Leuprolide 3Itraconazole 3Imiquimod 3Granulocyte-Macrophage Colony-Stimulating Factor 3Golytely 3Cryotherapy 3Abiraterone Acetate 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3abiraterone 2Yoga 2Topotecan 2Testosterone 2Tablets 2Simvastatin 2Radiosurgery 2Palliative Care 2Midazolam 2Gelatin 2Decision Support Techniques 2Collagenases 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Interventional × Infliximab × Clear all
NCT00004941 2015-03-25

Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease

FDA Office of Orphan Products Development

Phase 3 Completed
94 enrolled
Gastrointestinal

Crohn Disease, Gastrointestinal Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡